J&J Portfolio Moves — Strategy Read-Across & NBTXR3 Implications
1. The Core Strategic Logic: Portfolio Darwinism Around Three Pillars
The pattern emerging from J&J's Q4 restated holdings is deliberate and consistent with the broader M&A posture they've been executing since 2023. J&J's pipeline strategy reflects a clearer prioritization of core therapeutic strengths — oncology and immunology — tempered by pragmatic responses to shifting market and regulatory dynamics.
The exits (Arrowhead, BiomX, Senseonics) share a common thread: all three were legacy relationships that no longer fit the refocused Innovative Medicine perimeter. The retentions (Legend, Protagonist) share the opposite trait: deep co-development hooks with strategic optionality on full acquisition.
J&J's approach is more than buying new companies — it is about strategically divesting slower-growth assets to unlock capital and management focus for redeployment into higher-growth opportunities. That is exactly what this holdings reshuffle illustrates in miniature.
2. The Three Pillars That Survive the Cull
Oncology — the anchor. J&J has a well-stocked portfolio in oncology and in prostate cancer specifically, for which it sells Zytiga, Akeega and Erleada. The $3.05bn acquisition of Halda Therapeutics and its RIPTAC platform confirms that oncology is where J&J is prepared to write large cheques for differentiated mechanisms. The lead candidate HLD-0915 targets prostate cancer, with new diagnoses projected to reach 1.7 million globally by 2030, and the once-daily therapy is designed to overcome mechanisms of resistance.
Immunology — the second pillar. Protagonist Therapeutics ($246M retained stake) is squarely here. The companies are co-developing an oral treatment for immune diseases, and J&J's decision to hold rather than exit signals continued conviction in the asset and optionality on a full buyout.
Neuroscience — the emerging third axis. The $14.6 billion acquisition of Intra-Cellular Therapies in January 2025 marked a rare example of J&J making a large move outside of its traditional strongholds, underscoring growing confidence that neuroscience can deliver both clinical impact and commercial durability. CAPLYTA delivered $240 million in sales in Q3 2025 alone, demonstrating how quickly an acquisition can become a core part of the growth story.
3. The NBTXR3/Nanobiotix Read-Across — What the Article Missed
This is the significant omission from the piece you shared. The J&J/Nanobiotix relationship is arguably more strategically committed than either Legend Biotech or Protagonist — and it has recently deepened, not widened.
Full operational control transfer: J&J completed the NANORAY-312 sponsorship transfer in the majority of regions, along with the transfer of full operational control of the Phase 3 study. This is not a passive equity stake — this is J&J taking the wheel of a pivotal oncology trial.
Amended financial terms that favour J&J's engagement: The amendment removes Nanobiotix's funding obligation for NANORAY-312, with J&J assuming nearly all remaining costs for the ongoing pivotal Phase 3 trial through completion. In exchange, J&J was released from select milestone payments — a classic trade that reduces J&J's optionality costs while deepening its operational lock-in.
The deal economics remain substantial: Potential milestone payments include $1.77bn for first programs including head and neck cancer and lung cancer, $650M for five new indications, $165M for Asian markets, and $220M per additional indication developed by Nanobiotix, with tiered double-digit royalties ranging from low 10s to low 20s.
Critical catalyst incoming: The critical milestone is completing NANORAY-312 recruitment in H1 2026, which will trigger the interim efficacy analysis — with J&J ready to file immediately given their sponsorship role. The CONVERGE randomized Phase 2 in unresectable Stage III lung cancer, initiated by J&J in January 2025, adds a second indication readout.
The Phase 1 data cascade for 2026 is also significant: clinical updates from ongoing or completed JNJ-1900 (NBTXR3) Phase 1 studies sponsored by Nanobiotix or MD Anderson in melanoma, lung cancer amenable to re-irradiation, pancreatic cancer, and esophageal cancer are expected in 2026.
4. Synthesis: What This Tells Us About J&J's Acquisition Playbook
| Signal | Interpretation |
| Exit Arrowhead, BiomX, Senseonics | Clearing non-core legacy stakes — discipline, not distress |
| Retain Legend Biotech (CARVYKTI, MM) | Cell therapy deepening; acquisition optionality preserved |
| Retain Protagonist (oral immunology) | Bolt-on acquisition likely; $246M stake is a down-payment |
| Full NANORAY-312 operational control | Strongest signal of all — J&J doesn't take operational control of assets it doesn't intend to commercialise |
| Halda ($3bn, RIPTAC oncology platform) | Confirms willingness to pay for novel mechanisms in solid tumours |
| Intra-Cellular ($14.6bn, neuroscience) | Signals neuroscience as third core pillar, not just two-pillar story |
The Duato doctrine ("value typically created by smaller deals") should be read as a preference, not a constraint. Acquirers have tended to target later-stage assets, ranging from Phase II through commercialisation, with J&J's acquisition of Intra-Cellular Therapies for $14.7 billion among the most notable transactions. When the science warrants it, J&J will write the large cheque.
5. Bottom Line for NBTXR3/Nanobiotix Positioning
The article's focus on Legend and Protagonist as "acquisition targets" is correct but incomplete. Nanobiotix sits in a structurally different category: J&J has already internalised the asset operationally (Phase 3 sponsorship, full operational control) and the deal economics are de-risked for J&J relative to a full buyout. The more relevant question isn't if J&J buys Nanobiotix, but at what point in the NANORAY-312 readout cycle does an acquisition become value-accretive vs. waiting for milestone triggers.
A positive interim efficacy readout in H2 2026 would almost certainly reprice that calculus sharply.